• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Methyl 2-Fluoro-4-iodobenzoate (CAS No. 204257-72-7): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 2-Fluoro-4-iodobenzoate, identified by its CAS number 204257-72-7, is a versatile and highly valuable intermediate in the realm of pharmaceutical synthesis. This compound, characterized by its fluoro and iodo substituents, has garnered significant attention in recent years due to its utility in the development of novel therapeutic agents. The strategic placement of the fluoro group at the 2-position and the iodo group at the 4-position of the benzoate core imparts unique reactivity and pharmacological properties, making it a cornerstone in synthetic organic chemistry and medicinal chemistry.

The significance of Methyl 2-Fluoro-4-iodobenzoate lies in its role as a building block for more complex molecules. The presence of both electronegative substituents enhances its compatibility with various functionalization strategies, enabling chemists to design intricate scaffolds for drug candidates. In particular, the iodo group serves as an excellent handle for cross-coupling reactions, such as Suzuki-Miyaura and Stille couplings, which are pivotal in constructing biaryl structures prevalent in many pharmacologically active compounds.

Recent advancements in pharmaceutical research have highlighted the importance of fluorinated aromatic compounds. The introduction of a fluoro group into a molecule can significantly alter its metabolic stability, binding affinity, and overall pharmacokinetic profile. For instance, fluoro-substituted benzoates have been shown to exhibit enhanced bioavailability and reduced susceptibility to degradation by metabolic enzymes. This has led to their incorporation into a wide range of drug candidates targeting various therapeutic areas, including oncology, central nervous system disorders, and infectious diseases.

In the context of oncology research, Methyl 2-Fluoro-4-iodobenzoate has been utilized in the synthesis of kinase inhibitors and other anti-cancer agents. The combination of the fluoro and iodo groups provides a scaffold that can be readily modified to interact with specific targets on cancer cells. For example, researchers have leveraged these groups to develop molecules that inhibit tyrosine kinases, which are overexpressed in many cancer types. The ability to perform site-selective functionalization makes this compound an indispensable tool in the chemist's arsenal.

The use of Methyl 2-Fluoro-4-iodobenzoate extends beyond oncology into other therapeutic domains. In central nervous system (CNS) drug discovery, fluorinated benzoates have been explored for their potential to cross the blood-brain barrier more effectively than their non-fluorinated counterparts. This property is crucial for developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, the compound's reactivity allows for the synthesis of ligands that interact with neurotransmitter receptors, offering new avenues for therapeutic intervention.

Infectious disease research has also benefited from the versatility of Methyl 2-Fluoro-4-iodobenzoate. The introduction of fluorine atoms can improve the antimicrobial properties of a molecule by enhancing its binding affinity to bacterial enzymes or viral proteins. For instance, fluoro-substituted benzoates have been investigated as potential inhibitors of bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial replication. By modifying this intermediate, researchers can fine-tune the pharmacological profile of their drug candidates to achieve greater efficacy against pathogens.

The synthetic methodologies employed in the preparation of Methyl 2-Fluoro-4-iodobenzoate are equally noteworthy. Traditional approaches often involve halogenation reactions followed by esterification to introduce the carboxylate functionality. However, modern synthetic strategies have focused on optimizing these processes to enhance yield and purity while minimizing waste. Catalytic methods, such as transition metal-catalyzed halogenations and cross-coupling reactions, have been particularly effective in achieving these goals. These advancements not only improve efficiency but also align with green chemistry principles by reducing hazardous byproducts.

The future prospects for Methyl 2-Fluoro-4-iodobenzoate are promising, given its broad applicability across multiple therapeutic areas. As research continues to uncover new biological targets and mechanisms, the demand for sophisticated intermediates like this one is expected to grow. Collaborative efforts between synthetic chemists and biologists will be crucial in harnessing its full potential. By leveraging cutting-edge synthetic techniques and computational modeling, scientists can accelerate the discovery and development of novel therapeutics that address unmet medical needs.

In conclusion, Methyl 2-Fluoro-4-iodobenzoate(CAS No. 204257-72-7) represents a critical component in modern pharmaceutical synthesis. Its unique structural features and reactivity make it an invaluable tool for designing innovative drug candidates across various therapeutic domains. As our understanding of disease mechanisms evolves and new synthetic methodologies emerge, this compound will undoubtedly continue to play a pivotal role in advancing medicinal chemistry and improving patient outcomes.

• 146014-66-6(Benzoic acid, 2-fluoro-6-iodo-, methyl ester)
• 501433-15-4(Benzoic acid, 2-fluoro-3,4-diiodo-, methyl ester)
• 1260830-14-5(methyl 2-fluoro-3-iodobenzoate)
• 124700-40-9(2-Fluoro-4-iodobenzoic acid)
• 625471-27-4(Methyl 2-Fluoro-5-iodobenzoate)
• 861905-21-7(Methyl 3-fluoro-5-iodo-4-methylbenzoate)
• 205750-82-9(ethyl 2-fluoro-4-iodo-benzoate)
• 124700-41-0(2-Fluoro-5-iodobenzoic acid)
• 501433-14-3(Methyl 2,6-difluoro-3-iodobenzoate)
• 773136-66-6(Ethyl 2-fluoro-5-iodobenzoate)